5180-19-8Relevant articles and documents
First non-ATP competitive glycogen synthase kinase 3 β (GSK-3β) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease
Martinez, Ana,Alonso, Mercedes,Castro, Ana,Pérez, Concepción,Moreno, Francisco J.
, p. 1292 - 1299 (2007/10/03)
Glycogen synthase kinase 3 β (GSK-3β) has a central role in Alzheimer′s disease (AD). Selective inhibitors which avoid τ hyperphosphorylation may represent an effective therapeutical approach to the AD pharmacotherapy and other neurodegenerative disorders